Current Report Filing (8-k)
March 20 2019 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 19, 2019
Date of Report (Date of earliest event reported)
GALA PHARMACEUTICAL INC.
(Exact name of registrant as specified in
its charter)
NEVADA
|
000-52044
|
42-1771014
|
(State or other jurisdiction of
|
(Commission File
|
(IRS Employer Identification No.)
|
incorporation)
|
Number)
|
|
|
|
|
18881 Von Karman Avenue, Suite 1440, Irvine, California
|
92612
|
(Address of principal executive offices)
|
(Zip Code)
|
(949) 851-9261
Registrant's telephone number, including area code
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form
8-K fi ling is intended to simultaneously satisfy the fi ling obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[_] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
[_]
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
ITEM 8.01 OTHER EVENTS
Audit update:
Gala Pharmaceutical Inc.,
(the “Company”) is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the
fiscal year ended November 30, 2018 (the “2018 Form 10-K”) because the Company has experienced unexpected delays in
its completion of the audit of its financial statements for the fiscal year ended November 30, 2018, due to the complexity and
significant scope of work required to account for certain transactions and related tax accounting. As a result, the Company requires
additional time to finalize its financial statements to be filed as part of the 2018 Form 10-K, and plans to file its Form 2018
10-K within the next 14 days.
Testing
License Update:
Gala Pharmaceutical Inc. had submitted an application to the city of Long Beach for cannabis testing
laboratory license. While Gala was pursuing to receive its building permit to build a cannabis testing laboratory, the city advised
Gala to apply for State application for licensing. Gala applied for State license in and received state license on December 10,
2018. Soon after receiving the license the state official contacted Gala for a facility tour. Such official had the impression
that that the lab was already built. However the lab was not build because Gala was still waiting on city of Long Beach to issue
build out permits. The state officials requested to surrender the state license voluntarily as a formality and re-apply for permanent
state license once the labs is completely build out. Since then Gala received the building permit from the City of Long Beach and
has started the build-out which is scheduled to be completed by May 19, 2019. Gala intends to resubmit the state application shortly.
Signatures
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: March 19, 2019
|
By:
|
/s/ Maqsood Rehman
|
|
|
Maqsood Rehman
|
|
Title:
|
Chief Executive Officer
|